Novartis

News

Mariana Oncology's chief executive Simon Read

Novartis digs deeper in radiopharma with $1.75bn Mariana buy

Novartis has struck another deal to strengthen its position in radiopharmaceuticals, agreeing to pay $1 billion upfront for radioligand therapy (RLT) developer Mariana Onc

News

NICE backs Novartis duo for NHS use in young glioma patients

An oral therapy that can allow children and adolescents with an aggressive form of brain cancer to be treated at home rather than in hospital has been recommended for use

News

Sanofi’s oral BTK programme gets back on track

Sanofi has chalked up another win in a clinical trial of its oral BTK inhibitor rilzabrutinib, setting up regulatory filings in its first indication – rare disorder immune

News

Novartis names ex-BMS CEO Caforio as chair amid strong Q1

Novartis has posted a healthy rise in sales and profits in the first full quarter since it separated from Sandoz and proposed former Bristol Myers Squibb’s chief executive

News

Novartis adds clinical-stage protein degrader from Arvinas

Novartis has accelerated its efforts to develop protein degrader therapies by licensing a prostate cancer candidate from Arvinas on the brink of starting phase 3 trials in

News

CHMP backs Novartis’ Fabhalta as first oral therapy for PNH

The March meeting of the EMA’s human medicines committee (CHMP) saw an approval recommendation for Novartis’ Fabhalta, on track to become the first oral monotherapy for ra

Novartis digs deeper in radiopharma with $1.75bn Mariana buy

NICE backs Novartis duo for NHS use in young glioma patients

Sanofi’s oral BTK programme gets back on track

Novartis names ex-BMS CEO Caforio as chair amid strong Q1

Novartis adds clinical-stage protein degrader from Arvinas

CHMP backs Novartis’ Fabhalta as first oral therapy for PNH

Praxis soars on rare childhood epilepsy trial data

How to meet your physicians where they are online

Novartis

Editor's Picks